GLMD vs. EDSA, BLRX, ORGS, PRPH, ALZN, OMGA, CMND, CNSP, GLTO, and AWH
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Edesa Biotech (EDSA), BioLineRx (BLRX), Orgenesis (ORGS), ProPhase Labs (PRPH), Alzamend Neuro (ALZN), Omega Therapeutics (OMGA), Clearmind Medicine (CMND), CNS Pharmaceuticals (CNSP), Galecto (GLTO), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry.
Galmed Pharmaceuticals vs.
Edesa Biotech (NASDAQ:EDSA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.
Edesa Biotech is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Galmed Pharmaceuticals' return on equity of -28.75% beat Edesa Biotech's return on equity.
Galmed Pharmaceuticals received 415 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 63.41% of users gave Galmed Pharmaceuticals an outperform vote.
In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Edesa Biotech. Galmed Pharmaceuticals' average media sentiment score of 0.00 beat Edesa Biotech's score of -0.02 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.
Edesa Biotech currently has a consensus price target of $21.00, indicating a potential upside of 782.35%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Galmed Pharmaceuticals.
Summary
Edesa Biotech beats Galmed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:GLMD) was last updated on 2/22/2025 by MarketBeat.com Staff
Free GLMD Stock Alerts